曲美他嗪联合氯吡格雷治疗冠心病心绞痛疗效及对患者心电图、血清超敏C反应蛋白和五聚素3的影响
|
摘要
目的:探讨曲美他嗪联合氯吡格雷在冠心病心绞痛患者中的治疗作用,分析治疗对患者血清中超敏C反应蛋白(hs-CRP)和血清五聚素3(PTX-3)的调节作用。方法:选择确诊为冠心病心绞痛的患者共86例,按照随机原则分两组,均43例,对照组应用氯吡格雷,观察组应用曲美他嗪和氯吡格雷,于治疗4周后观察疗效,在治疗前、治疗2周后观察hs-CRP和PTX-3的含量。结果:两组治疗的总有效率差别有统计学意义。治疗后两组hs-CRP和PTX-3均下降,但观察组的下降值更明显。结论:二种药物联合治疗的临床疗效明显,对血清中hs-CRP和PTX-3的表达有明显下调作用,对维持内环境中的细胞因子平衡有一定价值,临床中可以积极应用。
Objective:To study effect on angina pectoris of coronary heart disease of trimetazidine combined with clopidogrel,analyze the serum change of hs-CRP and PTX-3. Methods :86 angina pectoris were divided into two groups by randomization methods. Control group(43 cases) was treated with clopidogrel. Observation group(43 cases) was treated with trimetazidine and clopidogrel. The curative effect and hs-CRP and PTX-3 levels was observed after 2 weeks. Results: The effect was significant difference in two groups. After treatment,expressions of hs-CRP and PTX-3 was decreased before and after treatment,but decreased value was more obvious in observation group than that in control group. Conclusion:Trimetazidine combined with clopidogrel is effective in coronary heart disease with angina pectoris. It can regulate the serum expression of hs-CRP and PTX-3,maintain balance of cytokines of internal environment.
Objective:To study effect on angina pectoris of coronary heart disease of trimetazidine combined with clopidogrel,analyze the serum change of hs-CRP and PTX-3. Methods :86 angina pectoris were divided into two groups by randomization methods. Control group(43 cases) was treated with clopidogrel. Observation group(43 cases) was treated with trimetazidine and clopidogrel. The curative effect and hs-CRP and PTX-3 levels was observed after 2 weeks. Results: The effect was significant difference in two groups. After treatment,expressions of hs-CRP and PTX-3 was decreased before and after treatment,but decreased value was more obvious in observation group than that in control group. Conclusion:Trimetazidine combined with clopidogrel is effective in coronary heart disease with angina pectoris. It can regulate the serum expression of hs-CRP and PTX-3,maintain balance of cytokines of internal environment.
引文
[1] 徐冬云,谢先余,韩金花,等.麝香保心丸对老年冠心病心绞痛血清TNF-α及Hs-CRP水平的影响[J].陕西中医,2016,37(9):1111-1112.
[2] 王艳,史玉红,李圣,等.氯吡格雷联合阿司匹林对冠心病心绞痛患者血清hs-CRP,TNF-α及IL-6水平的影响[J].现代生物医学进展,2017,17(2):327-330.
[3] 孙雨华,张正海,张海滨,等.参松养心胶囊治疗冠心病稳定型心绞痛疗效及对hs-CRP、NT-proBNP的影响[J].现代中西医结合杂志,2016,25(19):2072-2074.
[4] Demir MT,Baydin A,Amanvermez R,et al.Comparison of pentraxin-3 and ischemia-modified albumin with troponin in early diagnosis of acute coronary syndrome[J].Bratisl Lek Listy,2018,119(8):509-512.
[5] 侯敏.比索洛尔联合参麦注射液治疗冠心病心力衰竭的长期疗效研究[J].河北医药,2017,39(4):537-539.
[6] 王三合,王治伦.曲美他嗪联合通心络胶囊治疗冠心病心绞痛疗效观察[J].陕西中医,2016,37(2):169-170.
[7] Lee CW,Hwang I,Park CS,et al.Innate immunity markers in culprit plaques of acute myocardial infarction or stable angina[J].Biomarkers,2012,17(3):209-215.
[8] Surlin P,Rauten AM,Silosi I,et al.Pentraxin-3 levels in gingival crevicular fluid during orthodontic tooth movement in young and adult patients[J].Angle Orthodontist,2012,82(5):833-833.
[9] Jie H,Li Y,Pu X,et al.Pentraxin 3,a predicator for 28-day mortality in patients with septic shock[J].Am J Med Sci,2017,353(3):242-242.
[10] 刘东敏.舒血宁联合曲美他嗪治疗冠心病心绞痛临床观察[J].中国实验方剂学杂志,2011,34(19):258-260.
[11] Fan Y,Li S,Li XL,et al.C-reactive protein as a predictor for poor collateral circulation in patients with chronic stable coronary heart disease[J].Annals of Medicine,2016,48(1-2):1-2.
[12] 李静.阿托伐他汀联合曲美他嗪治疗冠心病心绞痛的疗效观察[J].实用心脑肺血管病杂志,2014,24(11):46-47.
[13] 姜春玲.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效及安全性分析[J].陕西医学杂志,2016,45(8):1064-1065.
[14] 贺文婷,秦越.曲美他嗪联合瑞舒伐他汀对急性冠脉综合征患者血清炎性因子和左心舒张功能的影响[J].陕西医学杂志,2016,45(11):1522-1523.
[15] Blaha MJ,Cainzos-Achirica M,Greenland P,et al.Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease:The multi-ethnic study of atherosclerosis (MESA)[J].Circulation,2016,133(9):849-858.
[16] Persic V,Bastiancic AL,Rosovic I,et al.Correlation between immunological-inflammatory markers and endothelial disfunction in the early stage of coronary heart disease.[J].Med Hypotheses,2018,115(5):72-73.
[17] Wu M,Gu X,Li X,et al.C-Reactive protein and inflammatory cytokines during percutaneous coronary intervention[J].J Vas Res,2016,53(1-2):39-41.
[18] Sugiyama T,Ishikawa S,Kotani K,et al.Relationship between serum high-sensitivity C-reactive protein and myocardial infarction in a general Japanese population[J].J Clin Lab Analysis,2016,30(6):999-1002.
[2] 王艳,史玉红,李圣,等.氯吡格雷联合阿司匹林对冠心病心绞痛患者血清hs-CRP,TNF-α及IL-6水平的影响[J].现代生物医学进展,2017,17(2):327-330.
[3] 孙雨华,张正海,张海滨,等.参松养心胶囊治疗冠心病稳定型心绞痛疗效及对hs-CRP、NT-proBNP的影响[J].现代中西医结合杂志,2016,25(19):2072-2074.
[4] Demir MT,Baydin A,Amanvermez R,et al.Comparison of pentraxin-3 and ischemia-modified albumin with troponin in early diagnosis of acute coronary syndrome[J].Bratisl Lek Listy,2018,119(8):509-512.
[5] 侯敏.比索洛尔联合参麦注射液治疗冠心病心力衰竭的长期疗效研究[J].河北医药,2017,39(4):537-539.
[6] 王三合,王治伦.曲美他嗪联合通心络胶囊治疗冠心病心绞痛疗效观察[J].陕西中医,2016,37(2):169-170.
[7] Lee CW,Hwang I,Park CS,et al.Innate immunity markers in culprit plaques of acute myocardial infarction or stable angina[J].Biomarkers,2012,17(3):209-215.
[8] Surlin P,Rauten AM,Silosi I,et al.Pentraxin-3 levels in gingival crevicular fluid during orthodontic tooth movement in young and adult patients[J].Angle Orthodontist,2012,82(5):833-833.
[9] Jie H,Li Y,Pu X,et al.Pentraxin 3,a predicator for 28-day mortality in patients with septic shock[J].Am J Med Sci,2017,353(3):242-242.
[10] 刘东敏.舒血宁联合曲美他嗪治疗冠心病心绞痛临床观察[J].中国实验方剂学杂志,2011,34(19):258-260.
[11] Fan Y,Li S,Li XL,et al.C-reactive protein as a predictor for poor collateral circulation in patients with chronic stable coronary heart disease[J].Annals of Medicine,2016,48(1-2):1-2.
[12] 李静.阿托伐他汀联合曲美他嗪治疗冠心病心绞痛的疗效观察[J].实用心脑肺血管病杂志,2014,24(11):46-47.
[13] 姜春玲.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效及安全性分析[J].陕西医学杂志,2016,45(8):1064-1065.
[14] 贺文婷,秦越.曲美他嗪联合瑞舒伐他汀对急性冠脉综合征患者血清炎性因子和左心舒张功能的影响[J].陕西医学杂志,2016,45(11):1522-1523.
[15] Blaha MJ,Cainzos-Achirica M,Greenland P,et al.Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease:The multi-ethnic study of atherosclerosis (MESA)[J].Circulation,2016,133(9):849-858.
[16] Persic V,Bastiancic AL,Rosovic I,et al.Correlation between immunological-inflammatory markers and endothelial disfunction in the early stage of coronary heart disease.[J].Med Hypotheses,2018,115(5):72-73.
[17] Wu M,Gu X,Li X,et al.C-Reactive protein and inflammatory cytokines during percutaneous coronary intervention[J].J Vas Res,2016,53(1-2):39-41.
[18] Sugiyama T,Ishikawa S,Kotani K,et al.Relationship between serum high-sensitivity C-reactive protein and myocardial infarction in a general Japanese population[J].J Clin Lab Analysis,2016,30(6):999-1002.